Research Analysts Offer Predictions for PTGX Q1 Earnings

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) – Analysts at HC Wainwright issued their Q1 2027 EPS estimates for shares of Protagonist Therapeutics in a report released on Monday, August 31st. HC Wainwright analyst D. Tsao expects that the company will post earnings per share of ($0.88) for the quarter. HC Wainwright currently has a “Buy” rating and a $170.00 target price on the stock. The consensus estimate for Protagonist Therapeutics’ current full-year earnings is $4.22 per share. HC Wainwright also issued estimates for Protagonist Therapeutics’ Q2 2027 earnings at ($0.89) EPS, Q3 2027 earnings at ($0.88) EPS and Q4 2027 earnings at ($0.15) EPS.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its earnings results on Wednesday, August 5th. The company reported $2.29 EPS for the quarter, topping analysts’ consensus estimates of $2.27 by $0.02. The firm had revenue of $213.47 million during the quarter, compared to the consensus estimate of $212.03 million. Protagonist Therapeutics had a net margin of 29.40% and a return on equity of 12.03%. The company’s revenue was up 3746.8% on a year-over-year basis.

A number of other research analysts also recently commented on the company. Wall Street Zen upgraded Protagonist Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 22nd. Citizens Jmp boosted their target price on Protagonist Therapeutics from $120.00 to $137.00 and gave the stock a “market outperform” rating in a research note on Wednesday, May 6th. Zacks Research downgraded Protagonist Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, August 7th. TD Cowen reiterated a “buy” rating on shares of Protagonist Therapeutics in a research note on Wednesday, July 1st. Finally, Wedbush increased their price target on shares of Protagonist Therapeutics from $118.00 to $173.00 and gave the company an “outperform” rating in a research note on Monday, August 10th. Sixteen research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $147.13.

Protagonist Therapeutics Price Performance

Protagonist Therapeutics stock opened at $146.49 on Wednesday. The stock has a market cap of $9.48 billion, a PE ratio of 142.22 and a beta of 1.78. The stock’s fifty day moving average is $139.71 and its two-hundred day moving average is $113.59. Protagonist Therapeutics has a 1-year low of $54.50 and a 1-year high of $160.81.

Institutional Investors Weigh In On Protagonist Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Johnson & Johnson acquired a new position in shares of Protagonist Therapeutics in the 2nd quarter valued at $300,220,852. NEXTBio Capital Management LP acquired a new stake in Protagonist Therapeutics during the 4th quarter worth $20,055,000. Deutsche Bank AG acquired a new stake in Protagonist Therapeutics during the 2nd quarter worth $17,387,000. Clearbridge Investments LLC purchased a new position in Protagonist Therapeutics during the 4th quarter worth $42,783,000. Finally, Stempoint Capital LP grew its position in Protagonist Therapeutics by 22.1% during the 1st quarter. Stempoint Capital LP now owns 72,577 shares of the company’s stock worth $7,650,000 after purchasing an additional 13,147 shares during the last quarter. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Insider Activity

In other news, Director William D. Waddill sold 9,000 shares of the business’s stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $117.94, for a total value of $1,061,460.00. Following the completion of the sale, the director directly owned 7,825 shares of the company’s stock, valued at approximately $922,880.50. The trade was a 53.49% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Dinesh V. Ph D. Patel sold 65,761 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $149.11, for a total value of $9,805,622.71. Following the completion of the sale, the chief executive officer directly owned 523,478 shares of the company’s stock, valued at approximately $78,055,804.58. This trade represents a 11.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 118,000 shares of company stock worth $16,921,379. Corporate insiders own 5.19% of the company’s stock.

More Protagonist Therapeutics News

Here are the key news stories impacting Protagonist Therapeutics this week:

• Positive Sentiment: Higher analyst price target: BMO Capital Markets raised its target for PTGX from $178 to $190 and maintained an “outperform” rating, implying approximately 29.7% upside from the referenced share price. The increase reflects greater confidence in MIMRYLO and Protagonist’s broader growth prospects.
• Positive Sentiment: MIMRYLO gains commercial potential: The FDA approval gives Protagonist an important marketed therapy for polycythemia vera, potentially creating a new revenue stream and strengthening the company’s position in hematology. Truist said the product could have meaningful commercial potential after approval. Protagonist Therapeutics’ MIMRYLO Holds Commercial Potential After FDA Approval
• Positive Sentiment: Pipeline and partner milestones remain catalysts: Wedbush views Protagonist’s proprietary pipeline as the main long-term growth driver, while additional Takeda milestones could further validate the company’s platform and provide potential payments or royalties. Protagonist Therapeutics’ Own Pipeline Seen as Main Long-Term Growth Driver
• Neutral Sentiment: Valuation and execution matter: With PTGX trading near its 12-month high and carrying a high price-to-earnings multiple, investors may demand strong MIMRYLO uptake, successful commercialization, and continued pipeline progress. The FDA decision is favorable, but sales execution and future clinical or regulatory milestones remain important.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral ?4?7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.